Skip to main content

Table 1 Comparison between Vildagliptin and Metformin on clinical, anthropometrical, and laboratory variables (intergroup and intragroup analysis)

From: 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study

Variables

Vildagliptin (baseline)

Vildagliptin (day 30)

Metformin (baseline)

Metformin (day 30)

Age (years)

39.05 ± 5.32

39.05 ± 5.32

39.79 ± 7.7

39.79 ± 7.7

Weight (kg)

94.96 ± 14.03

95.05 ± 14.14

99.51 ± 16.11

98.69 ± 15.70*

BMI (kg/m2)

36.03 ± 3.96

35.63 ± 4.10

38.48 ± 6.12

37.29 ± 5.92

Waist circumference (cm)

105.59 ± 10.5

–

106.55 ± 12.05

–

Hip circumference (cm)

116.06 ± 8.99

–

122.68 ± 11.95

–

WHR

0.91 ± 0.05

–

0.88 ± 0.07

–

Systolic BP (mmHg)

125.7 ± 11.91

122.2 ± 12.44

129.1 ± 18.41

122.3 ± 12

Diastolic BP (mmHg)

75.58 ± 13.41

72.26 ± 9.33

75.84 ± 10.37

73.79 ± 8.28

Heart rate (bpm)

75.68 ± 12.68

69.84 ± 10.49

70.05 ± 12.95

73.11 ± 10.89

Fat mass (%)

39.55 ± 3.95

39.32 ± 3.87

41.10 ± 4.25

41.36 ± 3.53

Lean mass (%)

60.45 ± 6.48

60.68 ± 3.87

59.20 ± 6.13

58.64 ± 3.53

Insulin (mIU/l)

1.76 ± 0.90

1.49 ± 0.73**

1.91 ± 1.17

1.57 ± 0.85

Glucose (mg/dl)

200.26 ± 95.07

193.08 ± 109

190.26 ± 74

153.6 ± 61.19***

HbA1c (%)

8.03 ± 1.79

7.37 ± 1.58

7.85 ± 2.03

7.2 ± 2.55

TC (mg/dl)

183.90 ± 36.74

182.1 ± 41.28

198.00 ± 37.8

187.8 ± 28.23 *

TG (mg/dl)

161.00 ± 79.84

148.4 ± 83.31

141.21 ± 78.66

153.9 ± 72.75

HDL-c (mg/dl)

43.00 ± 8.19

44.11 ± 9.35

46.73 ± 11.28

44.32 ± 9.62*

LDL-c (mg/dl)

108.60 ± 26.28

105.6 ± 23.24

112.90 ± 25.89

112.6 ± 22.57*

VLDL-c (mg/dl)

32.26 ± 15.97

26.44 ± 9.51

28.26 ± 15.73

30.89 ± 14.55

CRP (mg/dl)

1.15 ± 1.38

0.89 ± 0.7

0.92 ± 0.62

0.75 ± 0.46

C-Peptide (ng/ml)

1.74 ± 0.91

1.64 ± 0.74*

1.78 ± 0.91

1.52 ± 0.50

Grelin (pg/ml)

45.58 ± 19.87

47.34 ± 23.28

44.32 ± 26.92

45.28 ± 33.36

GIP (pg/ml)

24.3 ± 14.6

20.48 ± 13.65

20.29 ± 12.28

23.65 ± 17.66

GLP-1 (pM/l)

1.15 ± 1.04

3.62 ± 3.61**

0.98 ± 0.67

1.47 ± 1.32 &

Leptin (pg/ml)

21,880 ± 19,430

21,460 ± 18,257

25,350 ± 13,330

26,250 ± 14,426

Glucagon (pg/ml)

23.47 ± 20.63

29.02 ± 26.4

31.46 ± 53.48

30.82 ± 46.98

Adiponectin (ng/ml)

11,950 ± 11,540

15,107 ± 18,173*

11,590 ± 6151

12,212 ± 6723

Resistin (ng/ml)

34.01 ± 11.45

36.5 ± 13.81

36.06 ± 18.74

35.93 ± 20.01

PP (pg/ml)

30.17 ± 24.19

35.02 ± 34.45

33.26 ± 34.8

29.72 ± 29.43

PYY (pg/ml)

39.24 ± 21.73

36.51 ± 29.42

38.76 ± 36.88

49.51 ± 31.45

IL-6 (pg/ml)

2.117 ± 1.37

2.018 ± 1.213

3.436 ± 4.04

2.69 ± 2.5

LDLox (U/l)

74.8 ± 31.33

67.31 ± 29.13*

62.13 ± 16.81

62.54 ± 20.04

NEFA (mmol/l)

0.67 ± 0.23

0.64 ± 0.24

0.63 ± 0.25

0.65 ± 0.19

TNF-α (pg/ml)

0.54 ± 0.61

0.42 ± 0.44

0.36 ± 0.90

0.73 ± 1.19**

Endothelin (pg/ml)

1.67 ± 0.55

1.49 ± 0.35

1.62 ± 0.55

1.62 ± 0.58

DPP4act (μM/ml/min)

9.37 ± 3.52

8.05 ± 3.49

9.65 ± 3.73

9.09 ± 3.52*

Urinary isoprostane (pg/Mmol/g/creatinine)

283.2 ± 299.8

233.4 ± 122.3

214.2 ± 123.9

223.9 ± 78.52

Plasma viscosity (30 mPa s)

1.84 ± 0.1

1.88 ± 0.23

1.88 ± 0.14

1.79 ± 0.13

Plasma Viscosity (50 mPa s)

1.84 ± 0.13

1.85 ± 0.21

1.81 ± 0.09

1.78 ± 0.12

  1. Data are expressed as mean ± SD
  2. BMI body mass index, BP blood pressure, HbA1c glycated hemoglobin, TC total cholesterol, TG triglycerides, HDLc high density lipoprotein cholesterol, LDLc low density lipoprotein cholesterol, VLDLc very low density lipoprotein cholesterol, GIP glucose-dependent insulinotropic peptide, GLP-1 glucagon-like peptide-1, PP pancreatic polypeptide, PYY peptide YY, IL-6 interleukin 6, LDLox oxidized low density lipoprotein, NEFA non esterified fatty acids, DPP4act dipeptidyl peptidase 4 activity
  3. * Intragroup comparisons: *P < 0.05; **P < 0.01; P < 0.001
  4. &Intergroup comparisons: &P < 0.05
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us